- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ABPRO Aktie jetzt für 0€ handeln | |||||
| Fr | Abpro Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Abpro Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 04.11. | Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager | 2 | GlobeNewswire (USA) | ||
| 03.11. | Abpro completes 1-for-30 reverse stock split to maintain Nasdaq listing | 1 | Investing.com | ||
| 03.11. | Abpro Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | Abpro Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Abpro Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.07. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.06. | Abpro Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.06. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.06. | Abpro Holdings, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 27.04. | Abpro Corporation: Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager | 246 | GlobeNewswire (Europe) | Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization... ► Artikel lesen | |
| 10.03. | Abpro Corporation: Abpro Statement on the Departure of Former CEO Ian Chan | 374 | GlobeNewswire (Europe) | WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening... ► Artikel lesen | |
| 19.12.24 | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | 1.091 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,070 | +0,83 % | Qiagen auf der Jefferies-Konferenz: Wachstumskurs trotz Herausforderungen | ||
| OLEMA PHARMACEUTICALS | 19,460 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | 0,00 % | Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug | ||
| NUVALENT | 107,08 | +2,72 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | +5,58 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| BIONTECH | 88,00 | +0,06 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | +0,05 % | Avidity startet Programm für frühzeitigen Zugang zu DMD44-Therapie | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,050 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ADMA BIOLOGICS | 15,950 | +1,69 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,940 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 36,500 | +5,80 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| EVOTEC | 5,162 | -0,77 % | Eilmeldung am Abend: EVOTEC SE zeigt unerwartete Stärke | ||
| PRAXIS PRECISION MEDICINES | 189,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,035 | 0,00 % | Is Recursion Pharmaceuticals a Meme Stock? |
Das Unternehmen ABPRO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,140 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABPRO HOLDINGS INC finden Sie auf Wallstreet Online.